Novel Prognostic Personalized Biomarker and Therapeutic Target in Blood Cancer Related Fibrosis

Objective

The objective of this ERC Proof of Concept is to demonstrate the clinical application and commercial viability of a specific driver of the innate immune system as a novel predictive biomarker and as a novel therapeutic target for the diagnosis and treatment of bone marrow fibrosis related to blood cancer. This proposed project builds upon recent findings of my deFiber ERC Starting Grant (Stg) project, where we identified this danger-associated molecular pattern complex as exactly as such a prognostic and predictive biomarker and importantly showed that targeting with a small molecular, oral, anti-cancer inhibitor reduced fibrosis but also the cancer cell burden, in the sense of a targetable biomarker.

Fields of science

• medical and health sciences › basic medicine › immunology
• medical and health sciences › clinical medicine › cancer

Programme(s)

• H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)

Topic(s)

• ERC-2020-POC - Call for proposals for ERC Proof of Concept Grant

Call for proposal

ERC-2020-PoC
See other projects for this call

Funding Scheme

ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Host institution

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Address

Dr Molewaterplein 40
3015 GD Rotterdam
Netherlands

Activity type

Higher or Secondary Education Establishments

EU contribution

€ 150 000

Beneficiaries (1)

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU contribution

€ 150 000

Address

Dr Molewaterplein 40
3015 GD Rotterdam

Activity type

Higher or Secondary Education Establishments